Grant received in 2021
DCCC has funded 195.000 DKK to the project
Today, the standard treatment offered to patients with non-small cell lung cancer is a combination of chemotherapy and photon based radiotherapy. Introducing proton therapy as an alternative to photon based radiotherapy holds promise of reduced radiation dose to the heart and lungs. This is expected to reduce toxicity and impact survival in fragile patients. The Danish Oncological Cancer Group has identified a group of patients not eligible for standard combination treatment, due to large tumor burden, poor performance status or co-morbidities. For these patients we will conduct a randomized trial comparing standard radiotherapy with proton therapy. To ensure the safety and efficacy of this trial, we will develop national strategies to ensure that breathing motion and anatomical changes are accounted for during the treatment course, thus ensuring the same precision for the two treatment modalities.
Multidisciplinary organisation
Dansk Onkologisk Lungekræft gruppes radioterapiudvalg (Danish Oncological Lung Cancer Proton therapy committee)
Project stakeholders
Rigshospitalet, Department of Oncology
- Morten Hiul Suppli, MD, PhD
- Cécile Peucelle, Medical Physicist, PhD
Odense University Hospital, Department of Oncology
- Tine Schytte, MD, Associated Professor
Vejle Hospital, Department of Oncology
- Charlotte Kristiansen, MD, PhD
- Rune Slot Thing, Medical Physicist, PhD
Aarhus University Hospital, Department of Oncology
- Ditte Sloth Møller, Medical Physicist, PhD. Primary contact, Mail: dittmoel@rm.dk
- Marianne Marquard Knap, MD, PhD
Aarhus University Hospital, Danish Centre for Particle Therapy
- Maria Fuglsang Jensen, Medical Physicist, PhD
- Hanna Rahbek Mortensen, MD, PhD